Literature DB >> 24800130

Identification and treatment of antidepressant tachyphylaxis.

Steven D Targum1.   

Abstract

Antidepressant tachyphylaxis describes a condition in which a depressed patient loses a previously effective antidepressant treatment response despite staying on the same drug and dosage for maintenance treatment. It has been suggested that antidepressant tachyphylaxis is a form of relapse related to evolving drug tolerance, but it is also clear that there are other possible reasons for the loss of treatment response unrelated to tolerance, such as medication nonadherence. It has been reported that depressed patients with "true" antidepressant tachyphylaxis may be less responsive to new treatment interventions. Therefore, it is important to identify these patients as part of a comprehensive treatment planning process.

Entities:  

Keywords:  Antidepressant; antidepressant tachyphylaxis; antidepressant tolerance; breakthrough depression; drug tolerance; major depressive disorder

Year:  2014        PMID: 24800130      PMCID: PMC4008298     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  24 in total

1.  Tolerance to therapeutic effects of antidepressants.

Authors:  B M Cohen; R J Baldessarini
Journal:  Am J Psychiatry       Date:  1985-04       Impact factor: 18.112

2.  Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.

Authors:  M Fava; S M Rappe; J A Pava; A A Nierenberg; J E Alpert; J F Rosenbaum
Journal:  J Clin Psychiatry       Date:  1995-02       Impact factor: 4.384

Review 3.  Do antidepressant and antianxiety drugs increase chronicity in affective disorders?

Authors:  G A Fava
Journal:  Psychother Psychosom       Date:  1994       Impact factor: 17.659

4.  Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition.

Authors:  J J Mann
Journal:  J Clin Psychopharmacol       Date:  1983-12       Impact factor: 3.153

5.  Tachyphylaxis in unipolar major depressive disorder.

Authors:  David A Solomon; Andrew C Leon; Timothy I Mueller; William Coryell; Jedediah J Teres; Michael A Posternak; Lewis L Judd; Jean Endicott; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

Review 6.  Depressive breakthrough.

Authors:  A A Nierenberg; J E Alpert
Journal:  Psychiatr Clin North Am       Date:  2000-12

7.  The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity.

Authors:  Anthony J Rothschild
Journal:  Compr Psychiatry       Date:  2008-05-13       Impact factor: 3.735

8.  Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.

Authors:  Anthony J Rothschild; Boadie W Dunlop; David L Dunner; Edward S Friedman; Alan Gelenberg; Peter Holland; James H Kocsis; Susan G Kornstein; Richard Shelton; Madhukar H Trivedi; John M Zajecka; Corey Goldstein; Michael E Thase; Ron Pedersen; Martin B Keller
Journal:  Psychopharmacol Bull       Date:  2009

Review 9.  Can long-term treatment with antidepressant drugs worsen the course of depression?

Authors:  Giovanni A Fava
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

Review 10.  Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments.

Authors:  S E Byrne; A J Rothschild
Journal:  J Clin Psychiatry       Date:  1998-06       Impact factor: 4.384

View more
  9 in total

Review 1.  The gut microbiome and mental health: advances in research and emerging priorities.

Authors:  Andrew P Shoubridge; Jocelyn M Choo; Alyce M Martin; Damien J Keating; Ma-Li Wong; Julio Licinio; Geraint B Rogers
Journal:  Mol Psychiatry       Date:  2022-03-02       Impact factor: 13.437

2.  Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series.

Authors:  Geraldine R Slean; Kornwipa Hemarat; Rahul N Khurana; Jay M Stewart
Journal:  Int J Retina Vitreous       Date:  2016-01-25

3.  Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants.

Authors:  Rui Lopes; José Carlos Alves; Raquel Garcia Rego
Journal:  Case Rep Med       Date:  2016-10-11

4.  Tachyphylaxis to the Sedative Action of Mirtazapine.

Authors:  Georgios Papazisis; Spyridon Siafis; Dimitrios Tzachanis
Journal:  Am J Case Rep       Date:  2018-04-07

5.  Association of cough hypersensitivity with tracheal TRPV1 activation and neurogenic inflammation in a novel guinea pig model of citric acid-induced chronic cough.

Authors:  Xianghuai Xu; Qiang Chen; Zhongmin Qiu; Cuiqin Shi; Hongmei Ding; Lan Wang; Hanjing Lv; Li Yu
Journal:  J Int Med Res       Date:  2018-06-07       Impact factor: 1.671

Review 6.  The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review.

Authors:  Koen Demyttenaere; Zeno Van Duppen
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

7.  Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment.

Authors:  Yuri E Rybak; Ka S P Lai; Rajamannar Ramasubbu; Fidel Vila-Rodriguez; Daniel M Blumberger; Peter Chan; Nicholas Delva; Peter Giacobbe; Caroline Gosselin; Sidney H Kennedy; Hani Iskandar; Shane McInerney; Paula Ravitz; Verinder Sharma; Ari Zaretsky; Amer M Burhan
Journal:  Depress Anxiety       Date:  2021-02-02       Impact factor: 6.505

Review 8.  Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases.

Authors:  Yaron Ilan
Journal:  J Pers Med       Date:  2022-08-10

Review 9.  Psychiatric Prescribing Patterns for Depression Treatment in an Outpatient Depression Clinic.

Authors:  Roberta E Wilson; Sarah J Choi; Sagar V Parikh; Jolene R Bostwick
Journal:  Psychopharmacol Bull       Date:  2020-03-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.